These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 38032456)

  • 21. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.
    Wang D; Bayliss S; Meads C
    Health Technol Assess; 2011 Jan; 15(5):iii-iv, 1-124. PubMed ID: 21281564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Passive and active immunization against respiratory syncytial virus for the young and old.
    Villafana T; Falloon J; Griffin MP; Zhu Q; Esser MT
    Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28525961
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
    Hashmi NA; Cosgrove JF; MacMahon P
    Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention of respiratory syncytial virus infections in high-risk infants by monoclonal antibody (palivizumab).
    Groothuis JR; Nishida H
    Pediatr Int; 2002 Jun; 44(3):235-41. PubMed ID: 11982888
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New strategies for control of respiratory syncytial virus infection.
    Nokes JD; Cane PA
    Curr Opin Infect Dis; 2008 Dec; 21(6):639-43. PubMed ID: 18978532
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.
    Griffin MP; Yuan Y; Takas T; Domachowske JB; Madhi SA; Manzoni P; Simões EAF; Esser MT; Khan AA; Dubovsky F; Villafana T; DeVincenzo JP;
    N Engl J Med; 2020 Jul; 383(5):415-425. PubMed ID: 32726528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Respiratory Syncytial Virus: Targeting the G Protein Provides a New Approach for an Old Problem.
    Tripp RA; Power UF; Openshaw PJM; Kauvar LM
    J Virol; 2018 Feb; 92(3):. PubMed ID: 29118126
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical relevance of prevention of respiratory syncytial virus lower respiratory tract infection in preterm infants born between 33 and 35 weeks gestational age.
    Carbonell-Estrany X; Bont L; Doering G; Gouyon JB; Lanari M
    Eur J Clin Microbiol Infect Dis; 2008 Oct; 27(10):891-9. PubMed ID: 18629558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection.
    Fenton C; Scott LJ; Plosker GL
    Paediatr Drugs; 2004; 6(3):177-97. PubMed ID: 15170364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.
    Frogel MP; Stewart DL; Hoopes M; Fernandes AW; Mahadevia PJ
    J Manag Care Pharm; 2010; 16(1):46-58. PubMed ID: 20131495
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Strategies for preventing respiratory syncytial virus.
    Forbes M
    Am J Health Syst Pharm; 2008 Dec; 65(23 Suppl 8):S13-9. PubMed ID: 19020197
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nirsevimab: review of pharmacology, antiviral activity and emerging clinical experience for respiratory syncytial virus infection in infants.
    Jorgensen SCJ
    J Antimicrob Chemother; 2023 May; 78(5):1143-1149. PubMed ID: 36922390
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis.
    Groothuis JR; Hoopes JM; Hemming VG
    Adv Ther; 2011 Feb; 28(2):110-25. PubMed ID: 21318605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection.
    Mejias A; Garcia-Maurino C; Rodriguez-Fernandez R; Peeples ME; Ramilo O
    Vaccine; 2017 Jan; 35(3):496-502. PubMed ID: 27692523
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Challenges in Maximizing Impacts of Preventive Strategies against Respiratory Syncytial Virus (RSV) Disease in Young Children.
    Zheng Z
    Yale J Biol Med; 2022 Jun; 95(2):293-300. PubMed ID: 35782467
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization.
    Raghunandan R; Lu H; Zhou B; Xabier MG; Massare MJ; Flyer DC; Fries LF; Smith GE; Glenn GM
    Vaccine; 2014 Nov; 32(48):6485-92. PubMed ID: 25269094
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection.
    Sanders SL; Agwan S; Hassan M; Bont LJ; Venekamp RP
    Cochrane Database Syst Rev; 2023 Oct; 10(10):CD009417. PubMed ID: 37870128
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estimating the impact of multiple immunization products on medically-attended respiratory syncytial virus (RSV) infections in infants.
    Rainisch G; Adhikari B; Meltzer MI; Langley G
    Vaccine; 2020 Jan; 38(2):251-257. PubMed ID: 31740097
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimal Respiratory Syncytial Virus intervention programmes using Nirsevimab in England and Wales.
    Hodgson D; Koltai M; Krauer F; Flasche S; Jit M; Atkins KE
    Vaccine; 2022 Nov; 40(49):7151-7157. PubMed ID: 36328884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.